25  ||| S:0 E:3 ||| CD
years  ||| S:3 E:9 ||| NNS
of  ||| S:9 E:12 ||| IN
small  ||| S:12 E:18 ||| JJ
molecular  ||| S:18 E:28 ||| JJ
weight  ||| S:28 E:35 ||| NN
kinase  ||| S:35 E:42 ||| NN
inhibitors ||| S:42 E:52 ||| NNS
:  ||| S:52 E:54 ||| :
potentials  ||| S:54 E:65 ||| NNS
and  ||| S:65 E:69 ||| CC
limitations  ||| S:69 E:81 ||| JJ
Deregulation  ||| S:81 E:94 ||| NN
of  ||| S:94 E:97 ||| IN
protein  ||| S:97 E:105 ||| NN
and  ||| S:105 E:109 ||| CC
lipid  ||| S:109 E:115 ||| JJ
kinase  ||| S:115 E:122 ||| JJ
activities  ||| S:122 E:133 ||| NNS
leads  ||| S:133 E:139 ||| VBZ
to  ||| S:139 E:142 ||| TO
a  ||| S:142 E:144 ||| DT
variety  ||| S:144 E:152 ||| NN
of  ||| S:152 E:155 ||| IN
pathologies ||| S:155 E:166 ||| NN
,  ||| S:166 E:168 ||| ,
ranging  ||| S:168 E:176 ||| VBG
from  ||| S:176 E:181 ||| IN
cancer  ||| S:181 E:188 ||| NN
inflammatory  ||| S:188 E:201 ||| JJ
diseases ||| S:201 E:209 ||| NNS
,  ||| S:209 E:211 ||| ,
diabetes ||| S:211 E:219 ||| NN
,  ||| S:219 E:221 ||| ,
infectious  ||| S:221 E:232 ||| JJ
diseases ||| S:232 E:240 ||| NNS
,  ||| S:240 E:242 ||| ,
and  ||| S:242 E:246 ||| CC
cardiovascular  ||| S:246 E:261 ||| JJ
disorders ||| S:261 E:270 ||| NNS
.  ||| S:270 E:272 ||| .
Protein  ||| S:272 E:280 ||| NN
kinases  ||| S:280 E:288 ||| NNS
and  ||| S:288 E:292 ||| CC
lipid  ||| S:292 E:298 ||| JJ
kinases  ||| S:298 E:306 ||| NNS
represent ||| S:306 E:315 ||| VBP
,  ||| S:315 E:317 ||| ,
therefore ||| S:317 E:326 ||| RB
,  ||| S:326 E:328 ||| ,
an  ||| S:328 E:331 ||| DT
important  ||| S:331 E:341 ||| JJ
target  ||| S:341 E:348 ||| NN
for  ||| S:348 E:352 ||| IN
the  ||| S:352 E:356 ||| DT
pharmaceutical  ||| S:356 E:371 ||| JJ
industry ||| S:371 E:379 ||| NN
.  ||| S:379 E:381 ||| .
In  ||| S:381 E:384 ||| IN
fact ||| S:384 E:388 ||| NN
,  ||| S:388 E:390 ||| ,
approximately  ||| S:390 E:404 ||| RB
one-third  ||| S:404 E:414 ||| JJ
of  ||| S:414 E:417 ||| IN
all  ||| S:417 E:421 ||| DT
protein  ||| S:421 E:429 ||| NN
targets  ||| S:429 E:437 ||| NNS
under  ||| S:437 E:443 ||| IN
investigation  ||| S:443 E:457 ||| NN
in  ||| S:457 E:460 ||| IN
the  ||| S:460 E:464 ||| DT
pharmaceutical  ||| S:464 E:479 ||| JJ
industry  ||| S:479 E:488 ||| NN
are  ||| S:488 E:492 ||| VBP
protein  ||| S:492 E:500 ||| NN
or  ||| S:500 E:503 ||| CC
lipid  ||| S:503 E:509 ||| JJ
kinases ||| S:509 E:516 ||| NN
.  ||| S:516 E:518 ||| .
To  ||| S:518 E:521 ||| TO
date ||| S:521 E:525 ||| NN
,  ||| S:525 E:527 ||| ,
30  ||| S:527 E:530 ||| CD
kinase  ||| S:530 E:537 ||| CD
inhibitors  ||| S:537 E:548 ||| NNS
have  ||| S:548 E:553 ||| VBP
been  ||| S:553 E:558 ||| VBN
approved ||| S:558 E:566 ||| VBN
,  ||| S:566 E:568 ||| ,
which ||| S:568 E:573 ||| WDT
,  ||| S:573 E:575 ||| ,
with  ||| S:575 E:580 ||| IN
few  ||| S:580 E:584 ||| JJ
exceptions ||| S:584 E:594 ||| NNS
,  ||| S:594 E:596 ||| ,
are  ||| S:596 E:600 ||| VBP
mainly  ||| S:600 E:607 ||| RB
for  ||| S:607 E:611 ||| IN
oncological  ||| S:611 E:623 ||| JJ
indications  ||| S:623 E:635 ||| NNS
and  ||| S:635 E:639 ||| CC
directed  ||| S:639 E:648 ||| VBN
against  ||| S:648 E:656 ||| IN
only  ||| S:656 E:661 ||| RB
a  ||| S:661 E:663 ||| DT
handful  ||| S:663 E:671 ||| NN
of  ||| S:671 E:674 ||| IN
protein  ||| S:674 E:682 ||| NN
and  ||| S:682 E:686 ||| CC
lipid  ||| S:686 E:692 ||| JJ
kinases ||| S:692 E:699 ||| NN
,  ||| S:699 E:701 ||| ,
leaving  ||| S:701 E:709 ||| VBG
70 ||| S:709 E:711 ||| CD
%  ||| S:711 E:713 ||| NN
of  ||| S:713 E:716 ||| IN
the  ||| S:716 E:720 ||| DT
kinome  ||| S:720 E:727 ||| JJ
untapped ||| S:727 E:735 ||| NN
.  ||| S:735 E:737 ||| .
Despite  ||| S:737 E:745 ||| IN
these  ||| S:745 E:751 ||| DT
successes  ||| S:751 E:761 ||| NNS
in  ||| S:761 E:764 ||| IN
kinase  ||| S:764 E:771 ||| JJ
drug  ||| S:771 E:776 ||| NN
discovery ||| S:776 E:785 ||| NN
,  ||| S:785 E:787 ||| ,
the  ||| S:787 E:791 ||| DT
development  ||| S:791 E:803 ||| NN
of  ||| S:803 E:806 ||| IN
kinase  ||| S:806 E:813 ||| JJ
inhibitors  ||| S:813 E:824 ||| NN
with  ||| S:824 E:829 ||| IN
outstanding  ||| S:829 E:841 ||| JJ
selectivity ||| S:841 E:852 ||| NN
,  ||| S:852 E:854 ||| ,
identification  ||| S:854 E:869 ||| NN
and  ||| S:869 E:873 ||| CC
validation  ||| S:873 E:884 ||| NN
of  ||| S:884 E:887 ||| IN
driver  ||| S:887 E:894 ||| NN
kinase ||| S:894 E:900 ||| NNS
( ||| S:900 E:901 ||| -LRB-
s ||| S:901 E:902 ||| LS
)  ||| S:902 E:904 ||| -RRB-
in  ||| S:904 E:907 ||| IN
diseases ||| S:907 E:915 ||| NNS
,  ||| S:915 E:917 ||| ,
and  ||| S:917 E:921 ||| CC
the  ||| S:921 E:925 ||| DT
emerging  ||| S:925 E:934 ||| VBG
problem  ||| S:934 E:942 ||| NN
of  ||| S:942 E:945 ||| IN
resistance  ||| S:945 E:956 ||| NN
to  ||| S:956 E:959 ||| TO
the  ||| S:959 E:963 ||| DT
inhibition  ||| S:963 E:974 ||| NN
of  ||| S:974 E:977 ||| IN
key  ||| S:977 E:981 ||| JJ
target  ||| S:981 E:988 ||| NN
kinases  ||| S:988 E:996 ||| NNS
remain  ||| S:996 E:1003 ||| VBP
major  ||| S:1003 E:1009 ||| JJ
challenges ||| S:1009 E:1019 ||| NNS
.  ||| S:1019 E:1021 ||| .
This  ||| S:1021 E:1026 ||| DT
minireview  ||| S:1026 E:1037 ||| NN
provides  ||| S:1037 E:1046 ||| VBZ
an  ||| S:1046 E:1049 ||| DT
insight  ||| S:1049 E:1057 ||| NN
into  ||| S:1057 E:1062 ||| IN
protein  ||| S:1062 E:1070 ||| NN
and  ||| S:1070 E:1074 ||| CC
lipid  ||| S:1074 E:1080 ||| JJ
kinase  ||| S:1080 E:1087 ||| JJ
drug  ||| S:1087 E:1092 ||| NN
discovery  ||| S:1092 E:1102 ||| NN
with  ||| S:1102 E:1107 ||| IN
respect  ||| S:1107 E:1115 ||| NN
to  ||| S:1115 E:1118 ||| TO
achievements ||| S:1118 E:1130 ||| NNS
,  ||| S:1130 E:1132 ||| ,
binding  ||| S:1132 E:1140 ||| JJ
modes  ||| S:1140 E:1146 ||| NNS
of  ||| S:1146 E:1149 ||| IN
inhibitors ||| S:1149 E:1159 ||| NN
,  ||| S:1159 E:1161 ||| ,
and  ||| S:1161 E:1165 ||| CC
novel  ||| S:1165 E:1171 ||| NN
avenues  ||| S:1171 E:1179 ||| NNS
for  ||| S:1179 E:1183 ||| IN
the  ||| S:1183 E:1187 ||| DT
generation  ||| S:1187 E:1198 ||| NN
of  ||| S:1198 E:1201 ||| IN
second-generation  ||| S:1201 E:1219 ||| JJ
kinase  ||| S:1219 E:1226 ||| JJ
inhibitors  ||| S:1226 E:1237 ||| NN
to  ||| S:1237 E:1240 ||| TO
treat  ||| S:1240 E:1246 ||| VB
cancers ||| S:1246 E:1253 ||| NNS
.  ||| S:1253 E:1255 ||| .
